H2020Индивидуална стипендия2015–2017

BlaC E-assay · Portable electrochemical assay system for on-chip quantitative estimation of bladder cancer biomarkers in real samples

„Хоризонт 2020“ — Действия „Мария Склодовска-Кюри“

Период: 2015-10-05 → 2017-10-04
Финансиране от ЕС: 195 455 €
Участници: 1
Схема: MSCA-IF-EF-ST

Линиите свързват координатора с партньорите.

Накратко на български

Разработва се преносимо устройство за откриване на биомаркери за рак на пикочния мехур чрез електрохимичен анализ. Ранната диагностика на това заболяване е важна за повишаване на шансовете за оцеляване на пациентите.

Този кратък обзор е генериран от изкуствен интелект

Кратко обяснение, генерирано от езиков модел по текста на CORDIS. Оригиналът е по-долу.

Резултати накратко

Portable electrochemical assay system for on-chip quantitative estimation of bladder cancer biomarkers in real samples

• Overall objective The objective of this project is to develop a microfluidic based electrochemical platform focused on the development of inexpensive, accurate, and reliable POC diagnostic devices for bladder specific cancer biomarker detection with multiplexing capabilities and bring them to a pre-commercial stage. Electrochemical sandwich ELISA, branch of electrochemical immunoassay have been increasingly attractive for use in biosensing application due to its highly sensitive, label-free, and real-time multiplexed detection of biomolecules. • Importance for society Cancer is a life-threatening disease and its various types may affect almost any organ in human. Among various cancer types, Bladder cancer (BCa) is one of major cancer and affect over 70,000 people every year in the United States alone. One of the best approaches to improve cancer survival rate is to diagnose it at an early stage. In spite of the rapid explosion of new technology platforms, traditional optical ELISA is used in clinical practice, which is laborious, time-consuming, require large sample volume and suffer from low sensitivity. On the other hand, recently proposed electrochemical sensors, which promise easy operation, accuracy, high sensitivity, low cost and compact size mainly suffer from background signals, non-specificity and selectivity in clinical samples. • Problem being addressed In this project attempts were made to find solutions for key issues of non-specificity, sensitivity and selectivity in clinical samples for sensitive detection. Attempts were made to solve the key issues via separation of assay chamber and detection chamber with innovative surface chemistry and microfluidic design with electrochemical detection techniques. The project started with the fabrication of hair comb structured gold electrode followed by its characterization. The scope of the project includes development of biosensor platform via separation of assay chamber and detection chamber with innovative surface chemistry, microfluidic design and electrochemical detection techniques, Further it include immobilization of antibodies on the biosensor matrix, evaluation of sensor detection range, specificity study, and prototype development.

Текст от CORDIS, на английски · Данни: CORDIS, © Европейски съюз

Цел на проекта

Cancer is a leading cause of death worldwide and the best approaches to improve cancer survival rate is to diagnose it at an early stage. In spite of the rapid explosion of new technology platforms, traditional optical ELISA is used in clinical practice, which is laborious, time-consuming, require large sample volume and suffer from low sensitivity. On the other hand, recently proposed electrochemical sensors which promise easy operation, accuracy, high sensitivity, low cost and compact size mainly suffer from background signals, non-specificity and selectivity in clinical samples. Therefore, there is an urgent need to solve the key issues in the development of clinically relevant and commercially viable technologies that enable screening of high-risk individuals for cancer at an early stage. The proposed program is to develop a reliable point-of-care (POC) diagnostic system based on a multidisciplinary approach of integrated microfluidic and electrochemistry for multiple biomarker detection in clinical samples. The proposal aims at finding solutions for key issues of non-specificity, sensitivity and selectivity in clinical samples for sensitive and multiplexed detection. The proposal will address the above mentioned challenges, via separation of assay chamber and detection chamber with innovative surface chemistry and microfluidic design with electrochemical detection techniques. Work will be focused on bladder cancer as a test model to solve the above mentioned issues. The proposed device will be of bench top size and have capabilities to detect a panel of 3 or more biomarkers simultaneously. The successful outcome of the project will result in high impact publications, technology know-how and IP, which will be used to design and develop a prototype device. A secondment at Applied Enzyme Technology Ltd, Gwent Group (GWENT) will be used to study optimization of sensor shelf life and to ensure the developed system meets industrial standards.

Оригинален текст от CORDIS (на английски).

Участници

UNIVERSITY OF BATH · BATHКоординаторОбединеното кралство